Consecutive patients over 18 years of age, diagnosed with hepatic encephalopathy were recruited at the emergency room service. An informed consent, signed by their families was collected. Patients?clinical characteristics, biochemical tests of renal function, hemoglobin, glucose, bilirubins and albumin levels were obtained along with a blood sample to analyze Mn. Patients evolution was followed up for 6 months.
Blood Mn in patients [median, (range)] [20.5, (10.5-39.5) ¦Ìg/L] were higher than blood levels from a group of healthy volunteers [7.5, (6.1-12.8) ¦Ìg/L] (P < 0.001). Among 9 patients studied four died, 2 women and 2 men, those patients showed higher (P = 0.032) Mn levels [28, (17-39.5) ¦Ìg/L] than those alive [13.5, (10.5-32) ¦Ìg/L] after the follow up period.
In this pilot study, Mn blood levels were higher in hepatic encephalopathy that died as consequence of the disease that those that survived in a 6 month follow up period. Blood Mn could be a potential prognosis factor for death in patients with hepatic encephalopathy.